CI-1040, another drug predicted by our prognostic model, is an oral inhibitor of extracellular signal-regulated kinase (MEK) [55], It is a new candidate for targeted treatment of HCC because of its potential antitumor efficacy [56]. Here, MAP2K7 is linked to hepatocellular carcinoma.